AJP - Heart Track the topics, authors and articles important to you
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 290: H2554-H2559, 2006. First published January 6, 2006; doi:10.1152/ajpheart.01221.2005
0363-6135/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/6/H2554    most recent
01221.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fryer, R. M.
Right arrow Articles by Reinhart, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fryer, R. M.
Right arrow Articles by Reinhart, G. A.

Blood pressure regulation by ETA and ETB receptors in conscious, telemetry-instrumented mice and role of ETA in hypertension produced by selective ETB blockade

Ryan M. Fryer,1 Pamela A. Rakestraw,1 Patricia N. Banfor,1 Bryan F. Cox,1 Terry J. Opgenorth,2 and Glenn A. Reinhart1

1Integrative Pharmacology and 2Metabolic Disease Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, Illinois

Submitted 18 November 2005 ; accepted in final form 4 January 2006


   ABSTRACT
TOP
 ABSTRACT
METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
The net contribution of endothelin type A (ETA) and type B (ETB) receptors in blood pressure regulation in humans and experimental animals, including the conscious mouse, remains undefined. Thus we assessed the role of ETA and ETB receptors in the control of basal blood pressure and also the role of ETA receptors in maintaining the hypertensive effects of systemic ETB blockade in telemetry-instrumented mice. Mean arterial pressure (MAP) and heart rate were recorded continuously from the carotid artery and daily (24 h) values determined. At baseline, MAP ranged from 99 ± 1 to 101 ± 1 mmHg and heart rate ranged between 547 ± 15 and 567 ± 19 beats/min (n = 6). Daily oral administration of the ETB selective antagonist A-192621 [10 mg/kg twice daily] increased MAP to 108 ± 1 and 112 ± 2 mmHg on days 1 and 5, respectively. Subsequent coadministration of the ETA selective antagonist atrasentan (5 mg/kg twice daily) in conjunction with A-192621 (10 mg/kg twice daily) decreased MAP to baseline values on day 6 (99 ± 2 mmHg) and to below baseline on day 8 (89 ± 3 mmHg). In a separate group of mice (n = 6) in which the treatment was reversed, systemic blockade of ETB receptors produced no hypertension in animals pretreated with atrasentan, underscoring the importance of ETA receptors to maintain the hypertension produced by ETB blockade. In a third group of mice (n = 10), ETA blockade alone (atrasentan; 5 mg/kg twice daily) produced an immediate and sustained decrease in MAP to values below baseline (baseline values = 101 ± 2 to 103 ± 2 mmHg; atrasentan decreased pressure to 95 ± 2 mmHg). Thus these data suggest that ETA and ETB receptors play a physiologically relevant role in the regulation of basal blood pressure in normal, conscious mice. Furthermore, systemic ETB receptor blockade produces sustained hypertension in conscious telemetry-instrumented mice that is absent in mice pretreated with an ETA antagonist, suggesting that ETA receptors maintain the hypertension produced by ETB blockade.

atrasentan; A-192621; endothelin; mouse; vasculature

AS THE UTILITY of the genetically altered mouse as a model of cardiovascular function continues to increase, it has become increasingly obvious that neurohumoral control of hemodynamic function and blood pressure in the "normal" mouse is not always similar to other mammalian species such as rat or dog. Recent studies have demonstrated that functional responses in the mouse aorta in the presence of a number of constrictor [phenylephrine, ANG II, urotensin II, and endothelin (ET)-1 (4, 8, 34)] and dilator [acetylcholine, adenosine, and histamine (4, 34)] substances are markedly different from responses observed in rats and other species. Moreover, blockade of the renin-angiotensin system produces greater reductions in arterial pressure in C57BL/6J mice than observed in rats, suggesting that blood pressure values in the mouse are more dependent on the endogenous renin-angiotensin system than in the rat (4). The endothelin system is important in blood pressure regulation in the rat (9, 30), dog (27), and primate (32, 33). Given that the ET and renin-angiotensin systems closely interact with regard to renin release and the regulation of vascular resistance (3) and the fact that the vascular reactivity in the mouse to ET-1 is markedly different from rats and humans (34, 41), we hypothesized that the overall contribution of ET and ET type A (ETA) and type B (ETB) receptors to blood pressure regulation in the mouse may be different from other animals.

ET-1 is a potent vasoconstrictor capable of exerting an array of physiological effects, including the potential to alter arterial pressure and circulatory function through interactions with ETA and ETB receptors (21, 25). As such, ET receptors may play an important role in the pathophysiology of cardiac, vascular, and renal diseases associated with regional and systemic vasoconstriction (15, 37).

The ETA and ETB receptors are each coded by a specific gene and possess some overlap in their tissue distribution (2, 16, 35).

In the peripheral vasculature, ETA receptors are expressed primarily on the surface membrane of vascular smooth muscle cells where they mediate, in large part, the potent and characteristically sustained vasoconstrictor response associated with administration of exogenous ET peptides (32). Administration of exogenous ET-1 to an intact animal produces a classic, transient hypotension and vasodilation that is mediated via ETB receptors through enhanced generation of nitric oxide and prostaglandin-related substances, a response that precedes ETA-mediated vasoconstriction (14, 38, 40). Other experimental data suggest that ETB receptors may mediate a portion of ET-induced vasoconstriction in some vascular beds, a response that may be mediated by ETB receptors expressed on vascular smooth muscle cells (18, 24, 26).

We have demonstrated in conscious primates that sustained hypertension produced by systemic ETB receptor blockade is mediated by ETA receptors (32), suggesting that ETB receptors are part of an important clearance mechanism in primates that limits circulating ET-1 stimulation of ETA receptors, thereby maintaining blood pressure at normal levels. Similar results were demonstrated by other investigators in the rat (9, 31) but were not observed in ETB-deficient mice that were administered an early generation peptidic ETA antagonist BQ-123 (28). Moreover, the role of ET and systemic and localized ET receptor subtypes in the control of basal blood pressure in mice remains controversial (13, 22, 42). It has been demonstrated that collecting duct-derived ET-1 is an important physiological regulator of systemic blood pressure in the mouse but that the collecting duct ETA receptor does not appear to modulate blood pressure under physiological conditions (1, 13). Additionally, other studies have failed to definitively demonstrate a critical role for systemic ETA receptors in basal blood pressure regulation in the mouse or have obtained only a weak, nonsignificant depressor response in the face of ETA blockade (22, 42).

Thus the present study characterizes the effects of sustained systemic ETB receptor blockade on arterial pressure homeostasis in normal and unrestrained conscious C57Bl/6 mice by using quantitative radiotelemetry techniques. Subsequently, we tested the hypothesis that the increase in arterial pressure produced by ETB receptor blockade is indirectly mediated by activation of the ETA receptor by using two unique experimental protocols. In a final study we also delineate the quantitative contribution of systemic ETA receptors in basal blood pressure homeostasis in the normal and unrestrained conscious mouse.


   METHODS
TOP
 ABSTRACT
 METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Telemetry Transmitter Implantation

C57Bl/6 mice (25–30 g) were instrumented with telemetry transmitters (PA-C20, Data Sciences International; St. Paul, MN). Briefly, mice were anesthetized via intraperitoneal injection of ketamine and xylazine (100 mg/kg, 2.0 ml; and 15 mg/kg, 0.3 ml, respectively; groups 1 and 2) or via induction and maintenance of anesthesia with volatile isoflurane (2.0%; group 3). A midline incision was made through the skin, the right common carotid artery was isolated under a dissecting microscope, and the catheter was threaded into the aortic arch. Through the same incision, the radiotransmitter was tucked under the skin and sutured into place with 7-0 silk (Ethicon; Somerville, NJ). Mice were allowed to recover for at least 1 wk. Subsequently, arterial pressure and heart rate were continuously recorded and are reported as 24-h means. All procedures were approved by Abbott Laboratories' Institutional Animal Care and Use Committee and carried out in American Association for Accreditation of Laboratory Animal Care-accredited facilities.

Dosing Groups and Drug Preparation

We used a dosing regimen similar to that employed in a previous study in primates to define the role of ETA receptors in ETB-induced hypertension whereby we demonstrated that 10 mg/kg, but not 0.1 or 1.0 mg/kg, of A-192621 twice daily produced hypertension in conscious primates (an effect that was completely abolished by atrasentan) (32). Atrasentan (ETA antagonist) and/or A-192621 (ETB antagonist) (39) were synthesized at Abbott Laboratories and administered as a suspension via oral gavage in 0.2% hydroxypropyl methylcellulose twice daily at 0.02 ml/g body wt.

Group 1. The effects of selective ETB blockade with or without coblockade of ETA receptors were delineated (Fig. 1A). After 5 days of baseline telemetry recording, A-192621 (10 mg/kg twice daily) was administered for 8 days (n = 6). Atrasentan (5 mg/kg twice daily) was administered concomitant with A-192621 during the last 3 days of A-192621 treatment. Subsequently, animals were allowed to recover for 3 days (Fig. 1A).


Figure 1
View larger version (29K):
[in this window]
[in a new window]
  		Fig. 1. Effect of endothelin type B receptor (ETB) blockade with A-192621 in the absence or presence of endothelin type A receptor (ETA) blockade with atrasentan after 5 days of baseline recording (A) on mean arterial pressure (MAP; B) and heart rate (C). *P < 0.05, **P < 0.01.

 
Group 2. A separate group of animals (n = 6) were implanted with telemetry transmitters to determine if prior blockade of ETA receptors would prevent hypertension produced by ETB blockade (Fig. 2A). After 5 days of baseline telemetry recording, atrasentan (5 mg/kg twice daily) was administered for 3 days alone before coadministration with A-192621 (10 mg/kg twice daily) for 3 days.


Figure 2
View larger version (21K):
[in this window]
[in a new window]
  		Fig. 2. Effect of ETA blockade with atrasentan in the absence or presence of ETB blockade with A-192621 after 5 days of baseline recording (A) on MAP (B) and heart rate (C). *P < 0.05, **P < 0.01.

 
Group 3. In a final group of animals (n = 10) and after 5 days of baseline telemetry recording, the contribution of ETA receptors to basal blood pressure was assessed via administration of atrasentan alone for 5 days (5 mg/kg twice daily; Fig. 3A).


Figure 3
View larger version (22K):
[in this window]
[in a new window]
  		Fig. 3. Effect of ETA blockade with atrasentan after 5 days of baseline recording (A) on MAP (B) and heart rate (C). **P < 0.01.

 
Statistical Analysis

Changes in mean arterial pressure (MAP) and heart rate from mean baseline during administration of atrasentan and/or A-192621 were determined with repeated-measures ANOVA with Dunnett's t-test (Prism 4.03), and statistical significance was determined at P < 0.05 and P < 0.01.


   RESULTS
TOP
 ABSTRACT
 METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Group 1

Baseline (days –5 to –1) 24-h MAP values ranged between 99 ± 1 and 101 ± 1 mmHg (Fig. 1B). Selective ETB blockade with A-192621 produced an immediate and graded increase in MAP (to 112 ± 1 mmHg on days 3 and 5) throughout the 5-day treatment period. Hypertension produced by ETB blockade was abolished by simultaneous blockade of ETA receptors with atrasentan, suggesting the importance of ETA receptors in hypertension elicited by ETB blockade; on days 6–8, MAP fell in a graded fashion to 89 ± 3 mmHg, a value significantly below baseline blood pressure values, suggesting the potential role of ETA receptors in the basal regulation of blood pressure. MAP returned toward baseline for the 3 posttreatment days (Fig. 1B). Baseline heart rate ranged between 548 ± 15 and 568 ± 19 beats/min. Selective ETB blockade with A-192621 produced a graded reduction in heart rate (to 482 ± 15 beats/min on day 3). Values remained below baseline on days 4 and 5. Heart rate transiently increased on day 6 in response to the fall in blood pressure produced by coblockade of ETA and ETB receptors. Although values were not different from baseline on day 6 after blockade of both ETA and ETB receptors, on days 7–8 heart rate was reduced relative to baseline.

Group sizes for each 24-h mean were as follows: n = 6 for all baseline telemetry values and days 1–7; n = 5 on day 8 (1 mouse was removed from study because of loss of telemetry pressure waveform integrity); n = 4 for recovery days 1–3 (1 additional mouse was removed from study because of loss of telemetry pressure waveform integrity).

Group 2

Selective ETA blockade with atrasentan produced an immediate and stable reduction in MAP (to 93 ± 3 mmHg) that was maintained for 3 days, suggesting an important role of ETA receptors in basal blood pressure homeostasis; baseline MAP ranged between 99 ± 4 and 101 ± 4 mmHg (Fig. 2B). Simultaneous administration of atrasentan and A-192621 produced no change in MAP (range = 93 ± 4 to 95 ± 4 mmHg), definitively demonstrating the importance of ETA receptors in the genesis of hypertension produced by ETB blockade. Baseline heart rate ranged between 570 ± 14 and 584 ± 12 beats/min (Fig. 2C). Although ETA blockade with atrasentan produced no statistically significant effects on heart rate relative to baseline, heart rate transiently increased after atrasentan administration (to 593 ± 8 beats/min). Subsequently, heart rate trended downward (to 554 ± 9 beats/min). Coadministration of A-192621 after 3 days of atrasentan treatment produced a significant reduction in heart rate (to 522 ± 14 beats/min; n = 6 per 24-h group mean).

Group 3

Selective ETA blockade with atrasentan produced an immediate and stable reduction in MAP (to 95 ± 2 mmHg) that was maintained for 5 days, demonstrating the essential role of ETA receptors in the regulation of normal blood pressure values; baseline MAP ranged between 101 ± 2 and 103 ± 2 mmHg (Fig. 3B). Baseline heart rate ranged between 555 ± 11 and 577 ± 13 beats/min (Fig. 3C). Although ETA blockade with atrasentan produced no statistically significant effects on heart rate relative to baseline, heart rate transiently increased after atrasentan administration (to 582 ± 15 beats/min). Subsequently, heart rate was modestly reduced on days 3–5 (to 534 ± 9 beats/min; n = 10 per 24-h group mean).


   DISCUSSION
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
We demonstrate in the conscious and unrestrained telemetry-instrumented mouse that systemic, selective blockade of ETB receptors produces sustained hypertension (average increase in blood pressure 10 ± 1 mmHg above baseline) that is maintained by ETA receptor stimulation (Figs. 1B and 2B). Furthermore, these data suggest that ETB receptors also play an important role in basal blood pressure regulation (Fig. 1B). Finally, we demonstrate that ETA receptors contribute to basal blood pressure values in normal, conscious mice because atrasentan, a selective ETA antagonist, produced sustained reductions in blood pressure to values significantly below baseline (average decrease = 7 ± 1 mmHg; Figs. 2B and 3B).

A clear understanding of the individual role of ET receptor subtypes in the control of blood pressure in the mouse is important given the recent finding that vascular constriction in the mouse in response to ET-1 is markedly different from that observed in rats and humans (41). Moreover, Russell and Watts (34) have demonstrated that the mouse vasculature responds differently not only from ET-1 but also from ANG II, an effect that was further substantiated in vivo by Cholewa and colleagues (4), who demonstrated distinct differences between mice and rats regarding blood pressure regulation by the endogenous renin-angiotensin system. Specifically, they demonstrated that infusion of captopril or losartan resulted in a 55–90% greater fall in blood pressure in mice compared with rats, suggesting that blood pressure regulation in the mouse is more dependent on the renin-angiotensin system than it is in rats.

Regarding the contribution of the endogenous endothelin system in the control of blood pressure in mice, Ohuchi and colleagues (28) have demonstrated that mice with the piebald (s) mutation of the ETB gene and reduced ETB receptor expression have elevated blood pressure relative to wild-type mice, even though plasma levels of immunoreactive ET-1 were not increased. Further, intra-arterial administration of BQ-788, an early-generation peptidic ETB receptor antagonist, increased aortic blood pressure acutely in wild-type mice but not in ETB–/s mice; whether plasma ET-1 levels were increased in response to acute ETB blockade was not tested. Similarly, acute administration of the ETA antagonist BQ-123 did not markedly alter blood pressure in hypertensive ETB-deficient animals. Although the apparent hypertension is consistent with the effects of ETB deficiency or ETB blockade in other species, it is not clear why the effects of acute receptor blockade in piebald mice differ from the present results. It is possible, however, that the disparate results are due to differences in experimental design (acute vs. chronic; n = 4), the pharmacological agents employed, or differences in mouse strain (C57Bl/6 mice in the present study vs. genetically modified mice on a 129/SvEv background).

In studies performed in rats, Gariepy and colleagues (12) have demonstrated that spotting-lethal (sl) rats, which carry a naturally occurring ETB gene deletion (11), are hypertensive and exhibit severe salt-sensitive hypertension (increase in MAP of 41 mmHg vs. sodium-deficient diet). Elmarakby et al. (9) have demonstrated that ETA blockade with atrasentan in these rats reduced systolic pressure to values similar to wild-type rats. In addition, ETA blockade with atrasentan at doses similar to those used in the present study attenuated salt-dependent increases in blood pressure to near normal levels, suggesting that ETA receptors play a physiologically significant role in maintaining the salt-dependent hypertension produced by ETB deficiency. Thus ETB receptor deficiency in mice and rats causes hypertension that is dependent, in large part, on activation of ETA receptors.

The underlying mechanism of hypertension produced by ETB receptor antagonism has been debated. Because ETB receptor stimulation can produce transient dilation of some vascular beds and transient hypotension in vivo (7, 23), it has been postulated that a loss of ETB-dependent vasodilation (resulting from ETB blockade) might increase vascular tone, accounting for elevations in blood pressure. This hypothesis, however, is not supported in the present study. Although it is possible that a loss of ETB-mediated vasodilatory tone may contribute to an acute circulatory response to systemic ETB blockade, the consistent ability of ETA blockade to abolish ETB-dependent hypertension in the present study in mice (whether administered before or after A-192621) and other studies in rats and primates (9, 32) suggests that indirect activation of ETA receptors is a major mechanism by which systemic ETB blockade produces hypertension. Moreover, this is the first study to demonstrate that reversal of the treatments (ETA blockade before ETB blockade) prevents the hypertension produced by ETB blockade alone (Fig. 2B), thereby demonstrating the essential role of ETA receptors in maintaining the sustained hypertension elicited by ETB blockade.

Finally, given the dominant role of the kidney in regulating arterial pressure, the renal effects of altered ETB activity must also be considered. Studies in the anesthetized rat (17, 19), the anesthetized dog (6), and conscious dog (36) demonstrate that low-level ET-1 or ETB receptor activation produces natriuretic and diuretic effects. Studies performed in isolated rat nephron segments are consistent with these in vivo observations (10, 29). Thus it has been hypothesized that at normal levels of endogenous activation, ETB receptors exert a natriuretic tone such that loss of this tone through ETB suppression or ETB blockade may produce antinatriuretic effects and therefore cause hypertension (20). Consistent with this hypothesis, recent elegant studies performed in the mouse have demonstrated that collecting duct-specific knockout of ET-1 causes hypertension (1), whereas collecting duct-specific suppression of ETA receptors has no effect on blood pressure (13). These studies suggest that collecting duct ETA receptors do not influence blood pressure in the mouse and may reflect the presence of another intrarenal population of ETA receptors that serve to modulate fluid and electrolyte balance (and blood pressure) independent of the collecting duct and that are antagonized by systemic exposure to an ETA-selective antagonist. In addition, other indirect mechanisms, such as changes in renal sympathetic tone or other neurohumoral factors, cannot be ruled out as potential mediators of hypotension produced by sustained ETA blockade.

The doses of A-192621 and atrasentan employed in the present study have been shown to produce similar effects on basal blood pressure in primates (32). Indeed, ETA receptor blockade with atrasentan (5 mg/kg twice daily) in telemetry-instrumented conscious primates immediately reduced MAP by ~10 mmHg, an effect that is sustained through 4 days of treatment, suggesting that ETA receptors play an important role in normal primate blood pressure homeostasis (33). However, until the present study the role of ETA receptors in the maintenance of blood pressure in the mouse was less clear. Kuwaki and colleges (22) suggested that ETA receptors do not play an important role in basal blood pressure homeostasis in mice because blood pressure in ETA receptor-deficient infant mice, ETA–/– was not different from homozygous wild-type mice, ETA+/+ (as measured by using the servo-null micropressure technique under halothane anesthesia). However, the results of the present study, in normal unrestrained conscious mice by using telemetry to capture 24-h blood pressure values, clearly demonstrate that ETA receptors contribute to the regulation of basal blood pressure in the intact mouse, an observation also consistent with studies performed in conscious primates (33) and dogs (27).

Studies performed in other species consistently demonstrate that plasma ET-1 increases dose dependently in the presence of ETB blockade and is exacerbated in the presence of concomitant ETA blockade in primates (32, 33) and rats (9). ETA blockade alone also increases ET-1 in conscious primates (33) and in rats (9) because of the functional blockade of the cellular internalization of the ETA-ET-1 complex (5). Although we were unable to assess changes in ET-1 levels in mice in the present study, the fact that ETA blockade abolished hypertension produced by inhibition of ETB receptors implies that circulating ET-1 likely increased in response to ETB blockade.

In the present study, ETB blockade with A-192621 produced sustained hypertension in mice concomitant with decreases in heart rate. Although the increase in blood pressure is likely a direct effect of reduced ET-1 clearance and increased ETA activation, A-192621-induced bradycardia likely reflects a compensatory reduction in heart rate to maintain blood pressure homeostasis. It is interesting to note, however, that during concomitant ETA/ETB blockade (days 2–3; Fig. 1C), heart rate decreased to values below baseline despite significant reductions in blood pressure. Thus, although heart rate fell in response to hypertension, the expected converse response did not occur as blood pressure was reduced by systemic ETA blockade. Curiously, heart rate also trended downward in mice after multiple days of selective ETA blockade with atrasentan (Figs. 2C and 3C) despite significant reductions in blood pressure. These data imply that ETA receptors may modulate heart rate via a currently undefined mechanism refractory to baroreflex control.

In summary, we report several novel findings related to the cardiovascular physiology of the mouse and the role of the ET system in blood pressure control. We demonstrate in the unrestrained conscious C57Bl/6 mouse that selective systemic inhibition of ETB receptors produces a sustained hypertension that is maintained by ETA receptor activation. Furthermore, the present data demonstrate that ETA and ETB receptors contribute to basal blood pressure homeostasis in conscious, normal mice, thereby highlighting the importance of the ETA and ETB receptor systems in blood pressure regulation in the mouse.


   ACKNOWLEDGMENTS
 
We gratefully acknowledge the expertise of William T. Noonan in the continued development of the mouse telemetry model.


   FOOTNOTES
 

Address for reprint requests and other correspondence: R. M. Fryer, Dept. of Integrative Pharmacology, R46R, Global Pharmaceutical Research and Development, Abbott Laboratories, 100 Abbott Park Rd., Abbott Park, IL 60064-6119 (e-mail: ryan.fryer{at}abbott.com)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Ahn D, Ge Y, Stricklett PK, Gill P, Taylor D, Hughes AK, Yanagisawa M, Miller L, Nelson RD, and Kohan DE. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest 114: 504–511, 2004.[CrossRef][Web of Science][Medline]
  2. Arai H, Hori S, Aramori I, Ohkubo H, and Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348: 730–732, 1990.[CrossRef][Medline]
  3. Berthold H, Munter K, Just A, Kirchheim HR, and Ehmke H. Stimulation of the renin-angiotensin system by endothelin subtype A receptor blockade in conscious dogs. Hypertension 33: 1420–1424, 1999.[Abstract/Free Full Text]
  4. Cholewa BC, Meister CJ, and Mattson DL. Importance of the renin-angiotensin system in the regulation of arterial blood pressure in conscious mice and rats. Acta Physiol Scand 183: 309–320, 2005.[CrossRef][Web of Science][Medline]
  5. Chun M, Lin HY, Henis YI, and Lodish HF. Endothelin-induced endocytosis of cell surface ETA receptors. Endothelin remains intact and bound to the ETA receptor. J Biol Chem 270: 10855–10860, 1995.[Abstract/Free Full Text]
  6. Clavell AL, Stingo AJ, Margulies KB, Brandt RR, and Burnett JC Jr. Role of endothelin receptor subtypes in the in vivo regulation of renal function. Am J Physiol Renal Fluid Electrolyte Physiol 268: F455–F460, 1995.[Abstract/Free Full Text]
  7. Cornet S, Pirotzky E, and Braquet P. Implication of different endothelin receptors in the vascular action of a hypertensive dose of ET-1 in rat. J Cardiovasc Pharmacol 22, Suppl 8: S239–S242, 1993.[Medline]
  8. Douglas SA, Sulpizio AC, Piercy V, Sarau HM, Ames RS, Aiyar NV, Ohlstein EH, and Willette RN. Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey. Br J Pharmacol 131: 1262–1274, 2000.[CrossRef][Web of Science][Medline]
  9. Elmarakby AA, Dabbs Loomis E, Pollock JS, and Pollock DM. ETA receptor blockade attenuates hypertension and decreases reactive oxygen species in ETB receptor-deficient rats. J Cardiovasc Pharmacol 44: S7–S10, 2004.[CrossRef][Web of Science][Medline]
  10. Garcia NH and Garvin JL. Endothelin's biphasic effect on fluid absorption in the proximal straight tubule and its inhibitory cascade. J Clin Invest 93: 2572–2577, 1994.[Web of Science][Medline]
  11. Gariepy CE, Cass DT, and Yanagisawa M. Null mutation of endothelin receptor type B gene in spotting lethal rats causes aganglionic megacolon and white coat color. Proc Natl Acad Sci USA 93: 867–872, 1996.[Abstract/Free Full Text]
  12. Gariepy CE, Ohuchi T, Williams SC, Richardson JA, and Yanagisawa M. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest 105: 925–933, 2000.[Web of Science][Medline]
  13. Ge Y, Stricklett PK, Hughes AK, Yanagisawa M, and Kohan DE. Collecting duct-specific knockout of the endothelin A receptor alters renal vasopressin responsiveness, but not sodium excretion or blood pressure. Am J Physiol Renal Physiol 289: F692–F698, 2005.[Abstract/Free Full Text]
  14. Gomez-Alamillo C, Juncos LA, Cases A, Haas JA, and Romero JC. Interactions between vasoconstrictors and vasodilators in regulating hemodynamics of distinct vascular beds. Hypertension 42: 831–836, 2003.[Abstract/Free Full Text]
  15. Goto K, Hama H, and Kasuya Y. Molecular pharmacology and pathophysiological significance of endothelin. Jpn J Pharmacol 72: 261–290, 1996.[Medline]
  16. Granger JP. Endothelin. Am J Physiol Regul Integr Comp Physiol 285: R298–R301, 2003.[Free Full Text]
  17. Harris PJ, Zhuo J, Mendelsohn FA, and Skinner SL. Haemodynamic and renal tubular effects of low doses of endothelin in anaesthetized rats. J Physiol 433: 25–39, 1991.[Abstract/Free Full Text]
  18. Haynes WG and Webb DJ. Endothelin as a regulator of cardiovascular function in health and disease. J Hypertens 16: 1081–1098, 1998.[CrossRef][Web of Science][Medline]
  19. Hoffman A, Abassi ZA, Brodsky S, Ramadan R, and Winaver J. Mechanisms of big endothelin-1-induced diuresis and natriuresis: role of ET(B) receptors. Hypertension 35: 732–739, 2000.[Abstract/Free Full Text]
  20. Kotelevtsev Y and Webb DJ. Endothelin as a natriuretic hormone: the case for a paracrine action mediated by nitric oxide. Cardiovasc Res 51: 481–488, 2001.[Free Full Text]
  21. Kramer BK, Ittner KP, Beyer ME, Hoffmeister HM, and Riegger GA. Circulatory and myocardial effects of endothelin. J Mol Med 75: 886–890, 1997.[CrossRef][Web of Science][Medline]
  22. Kuwaki T, Ishii T, Ju K, Yanagisawa M, and Fukuda Y. Blood pressure of endothelin-3 null (–/–) knockout mice and endothelin A receptor null (–/–) knockout mice under anaesthesia. Clin Sci (Lond) 103, Suppl 48: 48S–52S, 2002.[Medline]
  23. Lavallee M and Thorin E. Role of ET-1 in the regulation of coronary circulation. Can J Physiol Pharmacol 81: 570–577, 2003.[CrossRef][Web of Science][Medline]
  24. Masaki T, Ninomiya H, Sakamoto A, and Okamoto Y. Structural basis of the function of endothelin receptor. Mol Cell Biochem 190: 153–156, 1999.[CrossRef][Web of Science][Medline]
  25. McNeill JR. Role of endothelin in regulation of resistance, fluid-exchange, and capacitance functions of the systemic circulation. Can J Physiol Pharmacol 81: 522–532, 2003.[CrossRef][Web of Science][Medline]
  26. Miyauchi T and Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 61: 391–415, 1999.[CrossRef][Web of Science][Medline]
  27. Munter K, Ehmke H, and Kirchengast M. Maintenance of blood pressure in normotensive dogs by endothelin. Am J Physiol Heart Circ Physiol 276: H1022–H1027, 1999.[Abstract/Free Full Text]
  28. Ohuchi T, Kuwaki T, Ling GY, Dewit D, Ju KH, Onodera M, Cao WH, Yanagisawa M, and Kumada M. Elevation of blood pressure by genetic and pharmacological disruption of the ETB receptor in mice. Am J Physiol Regul Integr Comp Physiol 276: R1071–R1077, 1999.[Abstract/Free Full Text]
  29. Plato CF, Pollock DM, and Garvin JL. Endothelin inhibits thick ascending limb chloride flux via ETB receptor-mediated NO release. Am J Physiol Renal Physiol 279: F326–F333, 2000.[Abstract/Free Full Text]
  30. Pollock DM. Contrasting pharmacological ETB receptor blockade with genetic ETB deficiency in renal responses to big ET-1. Physiol Genomics 6: 39–43, 2001.[Abstract/Free Full Text]
  31. Pollock DM and Pollock JS. Evidence for endothelin involvement in the response to high salt. Am J Physiol Renal Physiol 281: F144–F150, 2001.[Abstract/Free Full Text]
  32. Reinhart GA, Preusser LC, Burke SE, Wessale JL, Wegner CD, Opgenorth TJ, and Cox BF. Hypertension induced by blockade of ETB receptors in conscious nonhuman primates: role of ETA receptors. Am J Physiol Heart Circ Physiol 283: H1555–H1561, 2002.[Abstract/Free Full Text]
  33. Reinhart GA, Preusser LC, Opgenorth TJ, Wegner CD, and Cox BF. Endothelin and ETA receptors in long-term arterial pressure homeostasis in conscious nonhuman primates. Am J Physiol Regul Integr Comp Physiol 279: R1701–R1706, 2000.[Abstract/Free Full Text]
  34. Russell A and Watts S. Vascular reactivity of isolated thoracic aorta of the C57BL/6J mouse. J Pharmacol Exp Ther 294: 598–604, 2000.[Abstract/Free Full Text]
  35. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, Goto K, and Masaki T. Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor. Nature 348: 732–735, 1990.[CrossRef][Medline]
  36. Sandgaard NC and Bie P. Natriuretic effect of non-pressor doses of endothelin-1 in conscious dogs. J Physiol 494: 809–818, 1996.[Abstract/Free Full Text]
  37. Schiffrin EL. Endothelin and endothelin antagonists in hypertension. J Hypertens 16: 1891–1895, 1998.[CrossRef][Web of Science][Medline]
  38. Teerlink JR, Breu V, Sprecher U, Clozel M, and Clozel JP. Potent vasoconstriction mediated by endothelin ETB receptors in canine coronary arteries. Circ Res 74: 105–114, 1994.[Abstract/Free Full Text]
  39. Von Geldern TW, Tasker AS, Sorensen BK, Winn M, Szczepankiewicz BG, Dixon DB, Chiou WJ, Wang L, Wessale JL, Adler A, Marsh KC, Nguyen B, and Opgenorth TJ. Pyrrolidine-3-carboxylic acids as endothelin antagonists. 4. Side chain conformational restriction leads to ETB selectivity. J Med Chem 42: 3668–3678, 1999.[CrossRef][Web of Science][Medline]
  40. Warner TD. Characterization of endothelin synthetic pathways and receptor subtypes: physiological and pathophysiological implications. Eur Heart J 14, Suppl I: 42–47, 1993.
  41. Wiley KE and Davenport AP. Endothelin receptor pharmacology and function in the mouse: comparison with rat and man. J Cardiovasc Pharmacol 44, Suppl 1: S4–S6, 2004.[CrossRef][Web of Science][Medline]
  42. Yuyama H, Sonoda R, Shibasaki K, Fujimori A, Sudoh K, Sasamata M, and Miyata K. Effect of single oral administration of YM598, a novel selective endothelin ETA receptor antagonist, on blood pressure in normotensive and hypertensive rats. Vascul Pharmacol 41: 27–34, 2004.[CrossRef][Web of Science][Medline]



This article has been cited by other articles:


Home page
 HypertensionHome page
E. Raichlin, A. Prasad, V. Mathew, B. Kent, D. R. Holmes Jr, G. M. Pumper, R. E. Nelson, L. O. Lerman, and A. Lerman
Efficacy and Safety of Atrasentan in Patients With Cardiovascular Risk and Early Atherosclerosis
Hypertension, September 1, 2008; 52(3): 522 - 528.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
G. Fink, M. Li, Y. Lau, J. Osborn, and S. Watts
Chronic Activation of Endothelin B Receptors: New Model of Experimental Hypertension
Hypertension, September 1, 2007; 50(3): 512 - 518.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
D. M. Pollock and M. P. Schneider
Clarifying Endothelin Type B Receptor Function
Hypertension, August 1, 2006; 48(2): 211 - 212.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/6/H2554    most recent
01221.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fryer, R. M.
Right arrow Articles by Reinhart, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fryer, R. M.
Right arrow Articles by Reinhart, G. A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2006 by the American Physiological Society.